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Enzyme-Linked Immunosorbent Assay for Unnary Albumin at Low Concentrations
Bernhard K. Kramer,1 Ute Jesse,1 Klaudla M. Ress,’ Reinhold-Michael SchmUiling,2 and Teut Risler’
We describe an enzyme-linked immunosorbent assay (ELIsA)
for urinary albumin. It requires only commercially available
reagents, can detect as little as 16 zg of albumin per liter,
and analytical recovery ranges from 92 to 116%. The assay
is simple, rapid, and inexpensive. Albumin excretion was 6.2
(SD 4.1) mg/24 h in healthy subjects (n = 40), 14.7 (SD 7.2)
mg/24 h in albumin-test-strip-negative Type I diabetics (n =
11), and 19.7 (SD 16.2) mg/24 h in patients with essential
hypertension (n = 12).
Additional Keyphrases: diabetes hypertension reference
interval
Slight (“micro”) albuminuria is thought to predict diabetic
nephropathy in patients whose urines are albumin-negative
by Albustix test strips (1-3), but at a stage that can be
reversed by sufficient metabolic control (4-6). Once albu-
minuria is detectable by the Albustix test, the development
of diabetic nephropathy usually can no longer be prevented.
It is therefore important to have a sensitive, reliable, rapid,
and inexpensive test available for urinary albumin. Exact
estimation of microalbuminuria is also of special interest in
control of hypertension and of patients with renal allografts
(7,8).
Various techniques have been used for measuring mi-
croalbuminuria: radial immunodiffusion (9, 10), immuno-
electrophoresis (11), radioimmunoassays (12-16), and en-
zyme immunoassays (16-21). The main disadvantages of
radioimmunoassays are isotope-related health and safety
hazards and the short shelf-life of reagents.
Our aim in this study was to develop a sensitive, simple,
and rapid immunoassay for measuring urinary albumin
with use of only commercially available reagents.
Materials and Methods
Materials
Reagents. Human serum albumin was obtained from
Behringwerke AG, Marburg, F.R.G. Bovine serum albumin
was obtained from Sigma, Taufkirchen, F.R.G.; casein,
gelatin, creatinine, 250 mLIL sulfuric acid, hydrogen perox-
ide (300 g/L), and all reagents for buffer solutions were
supplied by Merck, Darmstadt, F.R.G. Tween 20
polyoxyethylene (20) sorbitan monolaurate, uric acid, urea,
globulins, and the enzyme substrate o-phenylenediamine
were from Serva, Heidelberg, F.R.G.
Antisera. Rabbit anti-human albumin antiserum (liquid;
cat. no. ORCBO4/05) was obtained from Berhringwerke AG,
and peroxidase-labeled goat anti-human albumin antise-
rum (lyophilized; cat. no. 3201-034) was from Cooper Bio-
medical, Frankfurt, F.R.G.
Assay diluent, pH 9.6. Antigen and antibodies are diluted
in 0.2 mol/L carbonate/bicarbonate buffer, prepared by dis-
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solving 16.72 g of NaHCO3 in 1 L of distilled water, and
adjusting to pH 9.6 with a solution of 21.1 g of Na2CO3 in 1
L of distilled water.
Washing solution. Dissolve 42.71 g of Na2HPO4 and 53.06
g of NaCl in 4 L of distilled water, adjust to pH 7.4 with a
mixture of 5.72 g of KH2PO4 and 6.14 g of NaC1 in 0.7 L of
distilled water. To 0.5 L of this phosphate-buffered saline
add 2.5 g of casein and 300 L of Tween 20.
Substrate solution. To 30 mg of o-phenylenediamine first
add 100 mL of freshly prepared 0.1 mol/L citrate buffer, pH
5.0(20.95 g of trisodium citrate dissolved in 0.7 L of distilled
water, adjusted to pH 5.0 with 6.3 g of citric acid dissolved in
0.3 L of distilled water), then add 30 pL of the concentrated
hydrogen peroxide solution. Prepare the substrate solution
in, and dispense it from, a brown bottle. Fresh preparation of
substrate solution before each run is recommended.
Standards. We prepared a stock 1 mg/L solution by
dissolving human serum albumin in the assay buffer; we
stored aliquots at -20 #{176}Cin tubes coated with the above-
described washing solution. From this stock solution we
prepared standards containing 0.03 to 8 mg per liter, in
assay buffer.
Equipment. Polystyrene microtiter plates were obtained
from Nunc, Wiesbaden, F.R.G. We measured absorbance
with a nliCrO-EuSA autoreader (MR 580; Dynatech, Denken-
dorf F.R.G.).
Samples
We collected 24-h urine specimens in polyethylene con-
miners that had been washed three successive times with
the washing solution before use. We stored 2-mL aliquots of
urine in tubes coated as described above at -20 #{176}Cfor not
longer than two months before assay. Urine samples were
centrifuged at 3700 x g and diluted 10-fold in assay buffer
before assay.
Patients
Urines from all patients and apparently healthy control
subjects were negative for albumin by #{176}Combur9-Test”
(Boehringer Mannheim GmbH, Mannheim, F.R.G.; detec-
tion limit for albumin 60 mgfL), and for leukocytes and
nitrite. Serum creatinine concentration was within the
normal reference interval in all subjects, and results of
routine clinical investigations were also within normal
limits. Mean (±SD) age was 39.4 ± 11.2 years (range 23-55,
n = 40) for the control subjects, 34.4 ± 10.4 years (range 22-
48, n = 11) for Type I diabetics, and 55.0 ±7.6 years (45-66,
n = 12) for patients with essential hypertension. For statis-
tical evaluation of data we used Student’s t-test.
ELISA Procedure
The ELISA was a solid-phase-binding double-antibody as-
say as described by Voller et al. (22). The procedure:
1. To sensitize the wells, incubate each well with 150 p.L
of rabbit anti-human albumin (diluted 5000-fold in assay
buffer), keeping the plates covered for 4 h at 4#{176}C.
2. After emptying the wells, wash them three times with
the washing solution, 150 pL per well. After the third wash
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incubate the plate for 30 mm at 20#{176}Cand then empty it,
tapping it while it is inverted on paper towelling. After
drying, it is ready to receive urine samples.
3. Pipette 100 L of standard solution, sample, or assay
buffer (as blank) into the wells in duplicate and incubate for
1.5 h at 20 #{176}C.
4. Wash the wells as described in step 2, but without the
incubation step.
5. To each well add 150 pL of peroxidase-labeled goat
anti-human albumin (diluted 5000-fold in assay buffer) and
incubate for 1 h at 20#{176}C.
6. Wash the wells again as described in step 4.
7. Add 150 ML of enzyme-substrate solution to each well
and incubate for 20 mm at 20#{176}C.Stop the reaction by
adding 50 L of sulfuric acid to each well.
8. Measure the absorbance of each well at 450 nm.
Results
Standard curve. The limit of detection (mean ±2 SD of
readings for 21 albumin-free wells) was 16 g/L, correspond-
ing to a sensitivity of 1.6 ng of human serum albumin per
well. The standard curve was linear over the range of 0.06 to
8.0 mg/L (Figure 1). A minimum of five standards is
recommended, and standards have to be run with each
plate.
Precision. Within-run precision was measured by assay-
ing three urine samples eight times in one assay (Table 1).
Between-run precision was estimated by assaying four
urine samples on 10 consecutive days (Table 1).
Accuracy. To check the specificity of the ELISA system, we
added urea, uric acid, creatinine, and a-, -, and y.globulins
to the assay buffer in their greatest physiological concentra-
tions and assayed. No cross reactivity was detected.
Analytical recovery. Recovery of low, middle, and high
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Fig. 1. Standard curve for human albuminin urine
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TabI
AlbumIn con
e 1. PrecisIon of the Method
en, mg/L
SD CV,%Mean
Within-run
4.19 0.386 9.2
1.05 0.053 5.1
0.10 0.008 7.6
Between-run
1.01 0.17 16.2
2.10 0.31 14.9
3.57 0.34 9.6
concentrations of human serum albumin was between 92.3
and 116.5% (Table 2). To demonstrate the absence of inter-
fering substances we diluted, with assay buffer, urines
having high, middle, and low concentrations of albumin
(38.7, 5.0, 1.6 mgJL). The results of the dilution experiment
are superimposable on the standard curve (Figure 1).
Albumin in 24-h urines. Using this ELISA, we measured
albumin excretion in albumin-test-strip-negative Type I
diabetics, in albumin-test-strip-negative patients with es-
sential hypertension, and in control subjects (Table 3). This
excretion was significantly (p <0.05) higher in the two
groups of patients than in the control subjects. We could
demonstrate no correlation between urinary albumin excre-
tion and age in either the control subjects (Table 4) or the
patients.
Discussion
This enzyme iinmunoassay (double-antibody “sandwich”
technique) is simple and rapid to perform; all the reagents
are both commercially available and inexpensive. Inter- and
intra-assay variations and analytical recovery were satisfac-
tory, although further improvements would probably be
possible if semi-automated techniques were used. The limit
of detection, 16 g/L, corresponds to 1.6 ng of albumin per
well, and is sufficiently low to detect above-normal albumin
concentrations (5.0 ng per well in control subjects). ELISA-
based urine-albumin assay techniques reported by several
Table 2. Analytical Recovery o
AlbumIn, mg/L
f Albumin
Recovery,%Added Measured
0.5 0.58 116
1.0 1.01 101
2.0 1.94 97
3.0 2.75 92
Table 3. Albumin Excretion (mg/24 h) by Control
Subjects and Patients
Mean± SD (and range)
Controls Type I diabetIcs Essentialhyportenslves
Females
6.6 ± 5.1 14.2 ± 4.8 23.3 ± 17.2
(0.7 - 21.0) (9.0 - 20.6) (4.6 - 50.4)
n=20 n= 5 n= 8
Males
5.4 ± 3.1 15.0 ± 9.2 12.6 ± 13.3(0.6 - 10.3) (3.3 - 30.9) (1.7 - 30.6)
n=20 n= 6 n= 4
Total
6.2 ± 4.1 14.7 ± 7.2 19.7 ± 16.2 -
(0.6 - 21.0) (3.3 - 30.9) (1.7 - 50.4)
n=40 n=11 n=12
Table 4. Relation between Age and Albumin Excretion
in Control Subjects
Age, y 20-30 31-40
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investigators (16-21) also give satisfactory results, but most
are either relatively time consuming and complicated or
require reagents that are not commerically available. Using
our immunoassay in clinical studies, the values we found for
albumin in 24-h urine specimens from normal controls
accorded well with results of other investigators (13, 14,20,
23). Above-normal excretions of albumin were demonstrat-
ed in patients with essential hypertension and Type I
diabetes, although routine laboratory methods (albumin-
test-strip, serum-creatinine) had shown normal results for
these subjects.
Others have reported conflicting results regarding age-
dependence of albumin excretion in healthy children (24,
25); we found no such correlation in adults (Table 4).
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